peri-menopause

Patients

One of the biggest challenges for women in their 40s and 50s going through the menopause is the recognition that one size does not fit all.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.